DEA’s June 29 Hearing Could Reshape the Future of Cannabis Capital Markets
The Coming Green Economy
DEA’s June 29 Hearing Could Reshape the Future of Cannabis Capital Market
The cannabis industry is once again approaching a historic crossroads.
On June 29, 2026, the U.S. Drug Enforcement Administration (DEA) will begin a new administrative hearing to determine whether marijuana should broadly move from Schedule I to Schedule III under the Controlled Substances Act.
For decades, cannabis businesses have operated inside a bizarre legal contradiction: legal under state law in much of America, but still treated federally as a Schedule I narcotic alongside heroin. That classification has kept the industry trapped outside traditional banking, institutional investing, senior stock exchanges, and mainstream capital markets.
Now the federal government appears to be reconsidering that position.
In April, the Department of Justice and DEA already issued a major shift by moving state-licensed medical marijuana operations and certain FDA-approved cannabis products into Schedule III classifications under federal law.
But the June 29 hearing is potentially much bigger.
The key question now becomes:
Will the DEA finally abandon the long-held federal position that all marijuana commerce constitutes “drug trafficking” under federal law?
If that wall begins to crack, the financial consequences could be enormous.
Today, many major financial institutions remain cautious because cannabis businesses still trigger anti-money laundering compliance issues, Suspicious Activity Reports (SARs), and federal criminal exposure. Even publicly traded cannabis companies face limitations with institutional banking, lending, custody services, and access to major exchanges.
A broader Schedule III framework could begin changing that.
Industry analysts believe the biggest immediate impact may come through the removal of IRS Code 280E penalties, which currently prevent cannabis operators from deducting ordinary business expenses.
But beyond taxes lies the real long-term prize:
institutional capital.
If federal agencies such as FinCEN, Treasury, and banking regulators begin treating licensed cannabis businesses more like regulated industries instead of criminal enterprises, Wall Street may finally enter the sector in force.
That could eventually open the door for:
Senior exchange listings
Traditional lending
Institutional banking
Expanded venture capital access
Retirement and pension fund exposure
Broader custody and clearing support
Large-scale mergers and acquisitions
Interstate investment expansion
Some legal experts caution that Schedule III alone does not fully legalize recreational cannabis federally. Adult-use marijuana businesses would still exist in a gray zone unless Congress acts further.
Still, many insiders believe the June hearing represents the first serious federal discussion about collapsing the distinction between state medical and recreational cannabis markets.
If federally recognized medical cannabis becomes normalized inside regulated state systems, pressure will grow rapidly to treat licensed recreational operators similarly — especially in states where the same companies operate both systems side-by-side.
That possibility has investors watching closely.
For years, cannabis entrepreneurs have argued that the industry cannot mature while federal regulators continue labeling licensed operators as traffickers despite billions in state tax revenue and legal commerce.
The June 29 DEA hearing may determine whether Washington is finally ready to move cannabis from the shadows of prohibition into the framework of regulated American capitalism.
And if that happens, cannabis may stop being viewed as an underground industry — and start being treated like a legitimate American commodity market.